Serum CA-125 Level after 6 Cycles of Primary Adjuvant Chemotherapy Is a Useful Prognostic Factor for Complete Responders’ Survival in Patients with Advanced Epithelial Ovarian Cancer
- 1 January 2008
- journal article
- Published by S. Karger AG in Onkologie
- Vol. 31 (6), 5
- https://doi.org/10.1159/000131270
Abstract
The aim of this study was to evaluate the prognostic value of the serum CA-125 level for complete responders after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy in advanced epithelial ovarian cancer. The clinical data of 123 complete responders after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy for epithelial ovarian cancer FIGO stages III and IV were collected between January 1997 and March 2007. All patients were divided into 3 groups according to the serum CA-125 level after 6 cycles of the chemotherapy: group I (< 10 U/ml), group II (10-21 U/ml), and group III (> 21 U/ml). The effect of the serum CA-125 level on survival was evaluated using the Kaplan-Meier method and Cox proportional hazard analysis. The median progression-free survival was 26, 14, and 10 months, and the median overall survival was 105, 42, and 37 months in groups I, II, and III, respectively (p < 0.05). The lower serum CA-125 level and optimal debulking surgery were prognostic factors for improving survival (p < 0.05). The serum CA-125 level after 6 cycles of primary adjuvant paclitaxel/carboplatin chemotherapy may be a good prognostic factor for survival in complete responders after 6 cycles of chemotherapy in advanced epithelial ovarian cancer.Keywords
This publication has 19 references indexed in Scilit:
- CA125 level as a predictor of progression-free survival and overall survival in ovarian cancer patients with surgically defined disease status prior to the initiation of intraperitoneal consolidation therapyGynecologic Oncology, 2007
- Pretreatment CA-125 and Risk of Relapse in Advanced Ovarian CancerJournal of Clinical Oncology, 2006
- Cancer Statistics, 2006CA: A Cancer Journal for Clinicians, 2006
- Survival and prognostic factors of women with advanced ovarian cancer and complete response after a carboplatin–paclitaxel chemotherapyGynecologic Oncology, 2005
- Systematic Aortic and Pelvic Lymphadenectomy Versus Resection of Bulky Nodes Only in Optimally Debulked Advanced Ovarian Cancer: A Randomized Clinical TrialJNCI Journal of the National Cancer Institute, 2005
- Does the nadir CA125 concentration predict a long-term outcome after chemotherapy for carcinoma of the ovary?Annals Of Oncology, 2005
- A Randomized Clinical Trial of Cisplatin/Paclitaxel Versus Carboplatin/Paclitaxel as First-Line Treatment of Ovarian CancerJNCI Journal of the National Cancer Institute, 2003
- Phase III Trial of Carboplatin and Paclitaxel Compared With Cisplatin and Paclitaxel in Patients With Optimally Resected Stage III Ovarian Cancer: A Gynecologic Oncology Group StudyJournal of Clinical Oncology, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses. Discrimination of benign from malignant diseaseAmerican Journal of Obstetrics and Gynecology, 1988